Jiangsu Aidea Pharmaceutical announced that its wholly-owned subsidiary, Yangzhou Aidi Medical Technology Co., Ltd., has received the approval notice for the marketing application of the chemical raw material, Enoviteline, issued by the National Medical Products Administration. Enoviteline active pharmaceutical ingredient corresponds to enoviteline tablets and enomitate tablets. The former is China's first approved oral medication for treating HIV-1 infection, and the latter is a combination of three antiviral medicines taken as a single daily dose for treating HIV-1.
艾迪药业：子公司艾诺韦林原料药获上市批准
Jiangsu Aidea Pharmaceutical: Its subsidiary, Enovate Pharmaceutical, obtains market approval for the active pharmaceutical ingredient.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.